CDK4/6 Inhibitors for Hormone-Driven Breast Cancer

home / insights / cdk-inhibitors-breast-cancer
CDK 4/6 Inhibitors in Metastatic Breast Cancer

EP. 1: CDK 4/6 Inhibitors in Metastatic Breast Cancer

October 2nd 2017
Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

EP. 2: Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017
CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

EP. 3: CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

October 2nd 2017
Abemaciclib for ER+ mBC

EP. 4: Abemaciclib for ER+ mBC

October 2nd 2017
Abemaciclib + Fulvestrant at Progression of HR+ mBC

EP. 5: Abemaciclib + Fulvestrant at Progression of HR+ mBC

October 2nd 2017
MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

EP. 6: MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

October 2nd 2017
MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

EP. 7: MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

October 2nd 2017
FDA Approval for Abemaciclib

EP. 8: FDA Approval for Abemaciclib

October 2nd 2017
CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

EP. 9: CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

October 2nd 2017
mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

EP. 10: mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

October 2nd 2017
Treatment Selection for HR+ mBC

EP. 11: Treatment Selection for HR+ mBC

October 2nd 2017
Future Directions: CDK4/6 Inhibitors in Breast Cancer

EP. 12: Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017
ER+/HER2+ Metastatic Breast Cancer

EP. 13: ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017
CDK4/6 Inhibitor Combinations for HR+ mBC

EP. 14: CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017
Understanding Abemaciclib: A New CDK4/6 Inhibitor

EP. 15: Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017
Heterogeneity of Metastatic HR+ Breast Cancer

EP. 16: Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017
Factors in Deciding Treatment for HR+ Breast Cancer

EP. 17: Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017
HR+ Breast Cancer: Resistance to Primary Therapy

EP. 18: HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017
HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

EP. 19: HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017
Abemaciclib's Value in Treating HR+ Breast Cancer

EP. 20: Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017
HR+ Breast Cancer: Updated Results From MONARCH Trials

EP. 21: HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017